Results 61 to 70 of about 14,154 (120)

Composition of the NRTI back-bone of the regimen started after the discontinuation of tenofovir (rows), according to the initial third drug (columns)–Selective tenofovir discontinuations.

open access: yes, 2016
Composition of the NRTI back-bone of the regimen started after the discontinuation of tenofovir (rows), according to the initial third drug (columns)–Selective tenofovir discontinuations.
Alessandro Cozzi-Lepri (195759)   +11 more
core   +1 more source

Evidence of toxicity in Adipose tissue of HIV-infected patients correlates with NRTI-associated mtDNA depletion

open access: yes, 2003
Background: The proposed basis for NRTI-associated fat wasting involves cellular mitochondrial DNA (mtDNA) depletion and mitochondrial dysfunction leading to clinical toxicities.
McKinnon, E.   +5 more
core  

A French national observatory of people with HIV initiating lenacapavir-based treatment after regulatory approval. [PDF]

open access: yesAntimicrob Agents Chemother
Charpentier C   +28 more
europepmc   +1 more source

HIV-1 genotypic patterns in antiretroviral-naïve and treated patients in the integrase inhibitor era in Morocco. [PDF]

open access: yesBMC Infect Dis
Ahmina M   +16 more
europepmc   +1 more source

Understanding integrase inhibitor resistance in Angola: a comparative analysis of INSTI-naive and INSTI-experienced individuals. [PDF]

open access: yesJ Antimicrob Chemother
Pocongo B   +19 more
europepmc   +1 more source

A French National Real-World Survey of People With Multiresistant HIV-1 Viruses Receiving an Antiretroviral Regimen Including Fostemsavir or Ibalizumab. [PDF]

open access: yesOpen Forum Infect Dis
Stefic K   +28 more
europepmc   +1 more source

Characterizing immune activation in HIV-exposed but uninfected infants in the first year of life. [PDF]

open access: yesFront Immunol
Roseto I   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy